Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Drug Administration and Therapy Phases: Overview01:26

Drug Administration and Therapy Phases: Overview

562
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
562
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.7K
Pharmacodynamics: Overview and Principles01:21

Pharmacodynamics: Overview and Principles

1.3K
Pharmacodynamics is a scientific field that delves into drugs' intricate biochemical, cellular, and physiological effects on the human body. The study of pharmacodynamics helps us understand how drugs interact with the body and elicit various responses.
Most drugs' effects result from their interactions with drug receptors or targets within the body. These interactions trigger specific responses at the cellular or systemic level. Drug receptors can be found on the surfaces of cells or...
1.3K
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

6.5K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
6.5K
Drug Clearance: Overview01:06

Drug Clearance: Overview

123
Drug elimination refers to drug removal from the body, either through urine or bile, by the kidneys or liver, respectively. A pharmacokinetic parameter, drug clearance, measures the efficiency of drug removal from the bloodstream within a specific time frame. It is calculated as the rate at which a drug is eliminated from plasma divided by the drug's concentration in plasma.
Drug clearance is not limited to renal excretion but encompasses all organs involved in drug elimination, including...
123
Drug Discovery: Overview01:26

Drug Discovery: Overview

8.1K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
8.1K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Enzyme-Activatable Fluorogenic Probes: Design Strategies, Biomedical Applications, and Future Perspectives.

Journal of the American Chemical Society·2026
Same author

Targeted degradation of hepatic KEAP1 mitigates drug-induced liver injury via dual boosting NRF2 and PGAM5 signaling.

Redox biology·2026
Same author

Salvianolic acid B attenuates drug-induced liver injury in an Nrf2-dependent mechanism via covalently modifying Keap1 at Cys395/Cys434.

Phytomedicine : international journal of phytotherapy and phytopharmacology·2026
Same author

Highly efficient discovery of CYP1B1 inhibitors from licorice as novel anti-fibrotic agents via integrating interdisciplinary methodologies.

Toxicology and applied pharmacology·2026
Same author

A flexible antigen-presenting cell targeting lentinan immunomodulator promotes stimulator of interferon gene-driven cancer therapy.

Carbohydrate polymers·2026
Same author

A Rationally Engineered MAGL-Activatable Fluorogenic Probe Enables Efficient Discovery of Anti-Inflammatory and Hepatoprotective Agents.

Journal of medicinal chemistry·2026

相关实验视频

Updated: Jul 26, 2025

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
10:29

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

1.3K

CYP1A抑制剂:最近的进展,当前的挑战和未来的前景.

Ziru Dai1, Yue Wu2, Yuan Xiong2

  • 1Key Laboratory of Bioactive Substances and Resources Utilization of Chinese Herbal Medicine, Ministry of Education, Institute of Medicinal Plant Development, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.

Medicinal research reviews
|June 20, 2023
PubMed
概括

人类细胞染色体P450 1A (CYP1A) 酶可以激活致癌物. CYP1A抑制剂提供了有前途的癌症化学预防,可以克服耐药性,帮助治疗发展.

关键词:
在CYP1A1中.在CYP1A2中.细胞染色体P450的使用.抑制剂 抑制剂 抑制剂结构-活动关系 (SARs).

更多相关视频

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
08:36

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Published on: April 7, 2023

1.1K
Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

11.4K

相关实验视频

Last Updated: Jul 26, 2025

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
10:29

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

1.3K
Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
08:36

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Published on: April 7, 2023

1.1K
Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

11.4K

科学领域:

  • 生物化学 生物化学
  • 药理学 药理学是指药理学的学科.
  • 药用化学 医学化学

背景情况:

  • 哺乳动物细胞P450 1A (CYP1A) 酶对于代谢异生菌,药物和内源性化合物至关重要.
  • 人类CYP1A亚家族 (hCYP1A1和hCYP1A2) 激活环境中致癌物质,将其转化为致癌形式.
  • 研究CYP1A抑制剂用于癌症化学预防和药物毒性/耐药性的管理.

研究的目的:

  • 审查最近人类CYP1A (hCYP1A) 抑制剂的发现和表征方面的进展.
  • 分析hCYP1A抑制剂的结构特征,结构-活性关系和生物医学应用.
  • 确定hCYP1A抑制剂研究中的挑战和未来方向.

主要方法:

  • 报告的hCYP1A抑制剂的综合摘要,包括抑制潜力,模式和常数.
  • 对hCYP1A1和hCYP1A2抑制剂的结构特征和结构-活性关系进行深入分析.
  • 发现方法和生物医学应用的审查.

主要成果:

  • 对各种hCYP1A抑制剂的抑制数据的详细摘要.
  • 对不同类型的hCYP1A1和hCYP1A2抑制剂的结构-活性关系的分析.
  • 识别抑制性活动的关键结构决定因素.

结论:

  • hCYP1A抑制剂代表了癌症化学预防和克服耐药性的有前途的治疗策略.
  • 对hCYP1A抑制剂的进一步研究将有助于开发有效的化学预防剂和研究工具.
  • 本综述为CYP1A抑制剂发现和开发领域的研究人员提供了宝贵的见解.